Cargando…

Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases

BACKGROUND AND AIM: Chronic kidney disease (CKD) and its final stage: end-stage renal disease (ESRD), are common clinical conditions. Endocan is a human endothelial cell-specific molecule produced by endothelial cells. Its production is related to activation of endothelium and angiogenesis. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Senosy, Fatma M., Abd El Aziz, Rasha Elsayed Mohamed, Kasim, Sammar Ahmed, Gad, Lamia Abdulbary, Hassan, Donia Ahmed, Sabry, Seham, El mancy, Ismail Mohamed, Shawky, Taiseer Ahmed, Mohamed, Ibrahim Ghounim Ramadan, Elmonier, Rady, Kotb, Essam, Abdul-Mohymen, Abeer Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300358/
https://www.ncbi.nlm.nih.gov/pubmed/35936065
http://dx.doi.org/10.1155/2022/4524637
_version_ 1784751195135410176
author El-Senosy, Fatma M.
Abd El Aziz, Rasha Elsayed Mohamed
Kasim, Sammar Ahmed
Gad, Lamia Abdulbary
Hassan, Donia Ahmed
Sabry, Seham
El mancy, Ismail Mohamed
Shawky, Taiseer Ahmed
Mohamed, Ibrahim Ghounim Ramadan
Elmonier, Rady
Kotb, Essam
Abdul-Mohymen, Abeer Mohammed
author_facet El-Senosy, Fatma M.
Abd El Aziz, Rasha Elsayed Mohamed
Kasim, Sammar Ahmed
Gad, Lamia Abdulbary
Hassan, Donia Ahmed
Sabry, Seham
El mancy, Ismail Mohamed
Shawky, Taiseer Ahmed
Mohamed, Ibrahim Ghounim Ramadan
Elmonier, Rady
Kotb, Essam
Abdul-Mohymen, Abeer Mohammed
author_sort El-Senosy, Fatma M.
collection PubMed
description BACKGROUND AND AIM: Chronic kidney disease (CKD) and its final stage: end-stage renal disease (ESRD), are common clinical conditions. Endocan is a human endothelial cell-specific molecule produced by endothelial cells. Its production is related to activation of endothelium and angiogenesis. In this study, we assessed the relation between serum endocan levels and subclinical atherosclerosis (SCA) in CKD and hemodialysis (HD) patients. SUBJECTS AND METHODS: The present case control study enrolled 30 patients on regular HD for at least 6 months, 30 patients with CKD, and 30 age and sex-matched healthy controls. All participants were subjected to careful history taking and thorough clinical examination. Laboratory investigations included complete blood count, kidney functions, and serum cholesterol, triglycerides, calcium, phosphorus, albumin, PTH, hsCRP, and endocan levels. RESULTS: HD and CKD groups had significantly higher endocan levels when compared with control group (median (IQR): 519.0 (202.3–742.0) versus 409.0 (245.3–505.3) and 273.0 (168.0–395.5) ng/L, respectively). Also, HD patients had significantly higher endocan levels when compared with CKD levels. HD patients had significantly higher carotid intima-media thickness (CIMT) when compared with CKD patients (median (IQR): 0.80 (0.80–0.90) versus 0.75 (0.73–0.75) mm, p < 0.001). HD patients had significantly higher frequency of SCA when compared with CKD patients (46.7% versus 13.3%, p=0.005). Patients with SCA had significantly higher hsCRP (median (IQR): 36.5 (26.8–43.5) versus 24.0 (15.8–29.0) mg/dl) and endocan levels (697.0 (528.3–974.8) versus 222.5 (158.8–565.8) ng/L) when compared with patients without SCA. ROC curve analysis of endocan for identification of SCA in HD patients showed that at a cutoff of 380.5 ng/L, endocan has an AUC of 0.862 with a sensitivity and specificity of 92.9% and 68.7%, respectively. CONCLUSIONS: Serum endocan levels are related to SCA in HD patients. In addition, it is associated with the hyperinflammatory state in those patients.
format Online
Article
Text
id pubmed-9300358
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-93003582022-08-04 Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases El-Senosy, Fatma M. Abd El Aziz, Rasha Elsayed Mohamed Kasim, Sammar Ahmed Gad, Lamia Abdulbary Hassan, Donia Ahmed Sabry, Seham El mancy, Ismail Mohamed Shawky, Taiseer Ahmed Mohamed, Ibrahim Ghounim Ramadan Elmonier, Rady Kotb, Essam Abdul-Mohymen, Abeer Mohammed Int J Clin Pract Research Article BACKGROUND AND AIM: Chronic kidney disease (CKD) and its final stage: end-stage renal disease (ESRD), are common clinical conditions. Endocan is a human endothelial cell-specific molecule produced by endothelial cells. Its production is related to activation of endothelium and angiogenesis. In this study, we assessed the relation between serum endocan levels and subclinical atherosclerosis (SCA) in CKD and hemodialysis (HD) patients. SUBJECTS AND METHODS: The present case control study enrolled 30 patients on regular HD for at least 6 months, 30 patients with CKD, and 30 age and sex-matched healthy controls. All participants were subjected to careful history taking and thorough clinical examination. Laboratory investigations included complete blood count, kidney functions, and serum cholesterol, triglycerides, calcium, phosphorus, albumin, PTH, hsCRP, and endocan levels. RESULTS: HD and CKD groups had significantly higher endocan levels when compared with control group (median (IQR): 519.0 (202.3–742.0) versus 409.0 (245.3–505.3) and 273.0 (168.0–395.5) ng/L, respectively). Also, HD patients had significantly higher endocan levels when compared with CKD levels. HD patients had significantly higher carotid intima-media thickness (CIMT) when compared with CKD patients (median (IQR): 0.80 (0.80–0.90) versus 0.75 (0.73–0.75) mm, p < 0.001). HD patients had significantly higher frequency of SCA when compared with CKD patients (46.7% versus 13.3%, p=0.005). Patients with SCA had significantly higher hsCRP (median (IQR): 36.5 (26.8–43.5) versus 24.0 (15.8–29.0) mg/dl) and endocan levels (697.0 (528.3–974.8) versus 222.5 (158.8–565.8) ng/L) when compared with patients without SCA. ROC curve analysis of endocan for identification of SCA in HD patients showed that at a cutoff of 380.5 ng/L, endocan has an AUC of 0.862 with a sensitivity and specificity of 92.9% and 68.7%, respectively. CONCLUSIONS: Serum endocan levels are related to SCA in HD patients. In addition, it is associated with the hyperinflammatory state in those patients. Hindawi 2022-07-13 /pmc/articles/PMC9300358/ /pubmed/35936065 http://dx.doi.org/10.1155/2022/4524637 Text en Copyright © 2022 Fatma M. El-Senosy et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
El-Senosy, Fatma M.
Abd El Aziz, Rasha Elsayed Mohamed
Kasim, Sammar Ahmed
Gad, Lamia Abdulbary
Hassan, Donia Ahmed
Sabry, Seham
El mancy, Ismail Mohamed
Shawky, Taiseer Ahmed
Mohamed, Ibrahim Ghounim Ramadan
Elmonier, Rady
Kotb, Essam
Abdul-Mohymen, Abeer Mohammed
Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases
title Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases
title_full Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases
title_fullStr Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases
title_full_unstemmed Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases
title_short Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases
title_sort serum endocan levels and subclinical atherosclerosis in patients with chronic kidney and end-stage renal diseases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300358/
https://www.ncbi.nlm.nih.gov/pubmed/35936065
http://dx.doi.org/10.1155/2022/4524637
work_keys_str_mv AT elsenosyfatmam serumendocanlevelsandsubclinicalatherosclerosisinpatientswithchronickidneyandendstagerenaldiseases
AT abdelazizrashaelsayedmohamed serumendocanlevelsandsubclinicalatherosclerosisinpatientswithchronickidneyandendstagerenaldiseases
AT kasimsammarahmed serumendocanlevelsandsubclinicalatherosclerosisinpatientswithchronickidneyandendstagerenaldiseases
AT gadlamiaabdulbary serumendocanlevelsandsubclinicalatherosclerosisinpatientswithchronickidneyandendstagerenaldiseases
AT hassandoniaahmed serumendocanlevelsandsubclinicalatherosclerosisinpatientswithchronickidneyandendstagerenaldiseases
AT sabryseham serumendocanlevelsandsubclinicalatherosclerosisinpatientswithchronickidneyandendstagerenaldiseases
AT elmancyismailmohamed serumendocanlevelsandsubclinicalatherosclerosisinpatientswithchronickidneyandendstagerenaldiseases
AT shawkytaiseerahmed serumendocanlevelsandsubclinicalatherosclerosisinpatientswithchronickidneyandendstagerenaldiseases
AT mohamedibrahimghounimramadan serumendocanlevelsandsubclinicalatherosclerosisinpatientswithchronickidneyandendstagerenaldiseases
AT elmonierrady serumendocanlevelsandsubclinicalatherosclerosisinpatientswithchronickidneyandendstagerenaldiseases
AT kotbessam serumendocanlevelsandsubclinicalatherosclerosisinpatientswithchronickidneyandendstagerenaldiseases
AT abdulmohymenabeermohammed serumendocanlevelsandsubclinicalatherosclerosisinpatientswithchronickidneyandendstagerenaldiseases